Luis E Fayad

Associate Professor

  • 10058 Citations
  • 55 h-Index
19962019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Luis E Fayad is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 29 Similar Profiles
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2019

1 Citation (Scopus)

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: A randomized phase 2 study

Strati, P., Fanale, M. A., Oki, Y., Turturro, F., Fayad, L. E., Bartlett, N. L., Gladstone, D. E., Kasamon, Y. L., Portlock, C. S., Wilson, W. H., Goy, A., Younes, A. & Lee, H. J., Jan 31 2019, In : Haematologica. 104, 2, p. e65-e67

Research output: Contribution to journalLetter

Hodgkin Disease
Rituximab
Follicular Lymphoma
Disease-Free Survival
Therapeutics
Biopsy
Radiotherapy
Marginal Zone B-Cell Lymphoma
Breast
Radiotherapy
Therapeutics
Salvage Therapy
Open Access
B-Cell Lymphoma
Names
Lymphoma
Neck
Radiotherapy

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

Pinnix, C. C., Milgrom, S. A., Cheah, C. Y., Gunther, J., Ludmir, E. B., Wogan, C. F., Nastoupil, L., Neelapu, S. S., Westin, J. R., Lee, H. J., Iyer, S. P., Steiner, R. E., Fayad, L. E., Fowler, N., Wang, L., Samaniego, F., Rodriguez, M. A., Rich, A. E., Medeiros, L. J. & Dabaja, B. S., Jan 1 2019, In : Blood Advances. 3, 9, p. 1356-1367 12 p.

Research output: Contribution to journalArticle

Open Access
Hodgkin Disease
Radiotherapy
Disease-Free Survival
Survival Rate
Therapeutics